Research opportunities for other movement disorders
Do you have cervical dystonia (CD) and are currently being treated with Botox? Is the therapeutic benefit of your injections lasting less than 10 weeks?
This study is looking at the therapeutic benefit of Xeomin, which is an FDA approved drug used to treat cervical dystonia, similar to Botox. The current standard of care for this treatment of CD includes injections into the affected neck muscles every 12 weeks. However, there is evidence to suggest that some patients may be experiencing significant loss of treatment effect within 10 weeks of injection. The purpose of this study is to evaluate the safety and efficacy of Xeomin in a short dosing period (6-10 weeks).
Participation in this study will last approximately 30-32 months and include 12-17 clinic visits. Subjects will be randomly assigned to participate in either the short dosing group (injections every 6-10 weeks) or the long dosing group (injections every 12 weeks). To qualify for this study, you must be diagnosed with cervical dystonia, received a least 3 Botox treatment injections over the last year, and receiving less than 10 weeks of treatment effect. Subjects will receive payment for their participation in this trial. Dr. Matthew Brodsky is the investigator for this study. For more information, please contact Kellie Kenis at 503-494-9531 or email@example.com. IRB# 8241